Back to Search
Start Over
Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting.
- Source :
- Journal of Correctional Health Care; Dec2022, Vol. 28 Issue 6, p368-371, 4p
- Publication Year :
- 2022
-
Abstract
- Incarcerated clients experience high rates of opioid use disorder and overdose. It is critical that opioid agonist treatment (OAT) is provided in correctional facilities. However, few receive OAT due to concerns about diversion, misuse, and safety. Buprenorphine extended-release (BUP-XR), a monthly buprenorphine depot injection, could be especially advantageous in the correctional setting as it can prevent diversion and misuse, saving staff resources and time. An injection of BUP-XR is costly compared with a monthly supply of buprenorphine/naloxone (BUP/NX) tablets. We demonstrate that when factoring in the added costs of medication preparation, administration, monitoring, and personnel, it is more economical to provide BUP-XR than BUP/NX. Other facilities, by utilizing our cost breakdown, can determine whether BUP-XR is economically advantageous at their own facility. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10783458
- Volume :
- 28
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- Journal of Correctional Health Care
- Publication Type :
- Academic Journal
- Accession number :
- 162311381
- Full Text :
- https://doi.org/10.1089/jchc.21.07.0063